Novo Nordisk A/S (NYSE:NVO) Stake Raised by Mitchell & Pahl Private Wealth LLC

Mitchell & Pahl Private Wealth LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,599 shares of the company’s stock after purchasing an additional 424 shares during the period. Mitchell & Pahl Private Wealth LLC’s holdings in Novo Nordisk A/S were worth $1,084,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in NVO. Hsbc Holdings PLC raised its position in shares of Novo Nordisk A/S by 19.4% during the second quarter. Hsbc Holdings PLC now owns 54,804 shares of the company’s stock worth $7,852,000 after purchasing an additional 8,922 shares during the period. AE Wealth Management LLC raised its holdings in shares of Novo Nordisk A/S by 161.5% during the second quarter. AE Wealth Management LLC now owns 19,319 shares of the company’s stock valued at $2,758,000 after acquiring an additional 11,930 shares during the period. Epoch Investment Partners Inc. lifted its position in shares of Novo Nordisk A/S by 4.5% in the 2nd quarter. Epoch Investment Partners Inc. now owns 14,132 shares of the company’s stock valued at $2,017,000 after acquiring an additional 614 shares in the last quarter. Gabelli Funds LLC boosted its stake in Novo Nordisk A/S by 35.7% in the 2nd quarter. Gabelli Funds LLC now owns 46,963 shares of the company’s stock worth $6,703,000 after purchasing an additional 12,363 shares during the period. Finally, DRW Securities LLC purchased a new position in Novo Nordisk A/S during the 2nd quarter worth approximately $1,298,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on NVO. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Trading Down 5.2 %

Shares of NYSE NVO opened at $78.74 on Tuesday. The stock has a market cap of $353.33 billion, a price-to-earnings ratio of 25.48, a PEG ratio of 0.84 and a beta of 0.45. The business has a 50 day simple moving average of $97.76 and a 200 day simple moving average of $116.89. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.